PMID- 16645011
OWN - NLM
STAT- MEDLINE
DCOM- 20060629
LR  - 20161018
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 154
IP  - 5
DP  - 2006 May
TI  - Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not 
      associated with hyper- or hypothyroidism per se, but is specifically sustained by 
      the autoimmune, inflammatory process.
PG  - 651-8
AB  - OBJECTIVE: Serum CXCL10 (an interferon-gamma-inducible chemokine) levels 
      (sCXCL10) are increased in several autoimmune conditions, including Graves' 
      disease (GD) and autoimmune thyroiditis (AT). Longitudinal assessment of sCXCL10 
      in autoimmune hypo- or hyperthyroidism has not yet been performed. DESIGN AND 
      METHODS: We longitudinally assayed sCXCL10 in the following groups: thirty-three 
      GD and 11 toxic nodular goiter (TNG) patients when hyperthyroid (Hyper) and when 
      reaching euthyroidism (Eu) with methimazole therapy (MMI) sixty-six AT (33 
      hypothyroid (Hypo) and 33 Eu) patients, basally and after reaching EU (for Hypo) 
      with levothyroxine (L-T4) therapy twenty-two patients with thyroid cancer (CA) 
      under L-T4-suppressive treatment, of whom 11 were re-evaluated after L-T4 
      withdrawal for diagnostic WBS, and 11 after recombinant TSH (rhTSH) 
      administration thirty-three healthy controls. RESULTS: At initial evaluation, 
      Hyper GD and AT (Hypo significantly higher than Eu) showed significantly higher 
      mean sCXCL10 than all other groups. MMI treatment led to a significant decrease 
      in sCXCL10 only in GD (not in TNG), while restoration of Eu, in Hypo AT, by L-T4 
      was not accompanied by significant sCXCL10 change. CA showed sCXCL10 comparable 
      to controls, and both Hypo after L-T4 withdrawal and rhTSH injection had no 
      effect on sCXCL10. CONCLUSIONS: Treatment of Hyper leads to a significant 
      decrease in sCXCL10 only in GD, and this probably depends upon the MMI 
      immunomodulatory effect. L-T4 correction of Hypo is not accompanied by 
      significant modification of sCXCL10 in AT. Increased sCXCL10 is not associated 
      with Hyper or Hypo per se, but is specifically sustained by the autoimmune 
      inflammatory event occurring in both GD and AT.
FAU - Antonelli, Alessandro
AU  - Antonelli A
AD  - Metabolism Unit, Department of Internal Medicine and CNR Institute of Clinical 
      Physiology, University of Pisa-School of Medicine, Via Roma, 67, I-56100, Pisa, 
      Italy. a.antonelli@med.unipi.it
FAU - Fallahi, Poupak
AU  - Fallahi P
FAU - Rotondi, Mario
AU  - Rotondi M
FAU - Ferrari, Silvia Martina
AU  - Ferrari SM
FAU - Romagnani, Paola
AU  - Romagnani P
FAU - Grosso, Mariano
AU  - Grosso M
FAU - Ferrannini, Ele
AU  - Ferrannini E
FAU - Serio, Mario
AU  - Serio M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokines, CXC)
SB  - IM
MH  - Adult
MH  - Chemokine CXCL10
MH  - Chemokines, CXC/*blood/*immunology
MH  - Female
MH  - Goiter, Nodular/blood/immunology/therapy
MH  - Graves Disease/blood/*immunology/therapy
MH  - Humans
MH  - Hyperthyroidism/blood/immunology/therapy
MH  - Hypothyroidism/blood/immunology/therapy
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Thyroid Gland/immunology
MH  - Thyroid Neoplasms/blood/immunology/therapy
MH  - Thyroiditis, Autoimmune/blood/*immunology/therapy
EDAT- 2006/04/29 09:00
MHDA- 2006/06/30 09:00
CRDT- 2006/04/29 09:00
PHST- 2006/04/29 09:00 [pubmed]
PHST- 2006/06/30 09:00 [medline]
PHST- 2006/04/29 09:00 [entrez]
AID - 154/5/651 [pii]
AID - 10.1530/eje.1.02137 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2006 May;154(5):651-8. doi: 10.1530/eje.1.02137.